| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -7,469 | 70,791 | -3,868 | -13,543 |
| Depreciation and amortization | 330 | 297 | 728 | 1,760 |
| Gain on sale of orthobiologics business | 425 | 80,211 | NaN | NaN |
| Loss on early repayment of debt | NaN | -1,287 | NaN | NaN |
| Loss (gain) on revaluation of warrant liability | 1,655 | -906 | -5,098 | -7,420 |
| Amortization of deferred financing costs and debt discount | NaN | NaN | 54 | 107 |
| Interest expense recorded as additional revenue interest obligation or long-term debt | 145 | -65 | 1,246 | 2,646 |
| Stock-based compensation | 931 | 872 | 1,982 | 2,360 |
| Bad debt expense | NaN | 458 | NaN | NaN |
| Payments on revenue interest obligation | NaN | 2,200 | NaN | NaN |
| Other | NaN | -608 | NaN | NaN |
| Changes in right-of-use assets and lease liabilities and lease incentives received | 320 | NaN | NaN | NaN |
| Accounts receivable | 334 | -1,361 | 403 | 874 |
| Inventory | 40 | 548 | -239 | 1,332 |
| Receivables of litigation costs | 502 | 285 | 264 | -463 |
| Prepaid expenses and other | -241 | 2,183 | -745 | -1,153 |
| Other liabilities | NaN | 1,068 | 97 | -33 |
| Accounts payable and accrued expenses | 542 | -9,855 | 2,287 | 1,021 |
| Contingent liability for legal proceedings | -3,225 | -5,142 | -632 | -3,417 |
| Net cash used in operating activities | -7,831 | -24,814 | -2,887 | -17,109 |
| Proceeds from sale of orthobiologics business | 425 | 80,435 | NaN | NaN |
| Expenditures for property and equipment | 459 | 854 | 630 | 392 |
| Net cash used in investing activities | -34 | 79,581 | -630 | -392 |
| Proceeds from public offering or private placement with warrants, net of offering costs | NaN | 13,795 | NaN | NaN |
| Proceeds from private placement and warrants, net of offering costs | NaN | NaN | 0 | 13,796 |
| Proceeds (repayments) of long-term debt, net | NaN | -23,064 | NaN | NaN |
| Repayments of insurance premium financings | NaN | 0 | 236 | 865 |
| Payments for taxes upon vesting of restricted stock units | 44 | 73 | 58 | 249 |
| Proceeds from stock option exercises and issuance common stock under espp | 47 | 0 | 32 | 80 |
| Net cash provided by financing activities | 3 | -23,138 | -262 | 12,762 |
| Net (decrease) increase in cash and cash equivalents | -7,862 | 31,629 | -3,779 | -4,739 |
| Cash and cash equivalents, beginning of period | 36,350 | 4,721 | 13,239 | NaN |
| Cash and cash equivalents, end of period | 28,488 | 36,350 | 4,721 | NaN |
ELUTIA INC. (ELUT)
ELUTIA INC. (ELUT)